Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells (Q36678312)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 November 2012

Language	Label	Description	Also known as
English	Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells	scientific article published on 10 November 2012

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells (English)

1 reference

Europe PubMed Central

15 August 2017

0 references

1 reference

based on heuristic

inferred from title

Maria Kavallaris

8

object named as

Maria Kavallaris

1 reference

Europe PubMed Central

15 August 2017

author name string

Eddy Pasquier

1

1 reference

Europe PubMed Central

15 August 2017

Maria-Pia Tuset

2

1 reference

Europe PubMed Central

15 August 2017

Janine Street

3

1 reference

Europe PubMed Central

15 August 2017

Snega Sinnappan

4

1 reference

Europe PubMed Central

15 August 2017

Karen L MacKenzie

5

1 reference

Europe PubMed Central

15 August 2017

Diane Braguer

6

1 reference

Europe PubMed Central

15 August 2017

Nicolas Andre

7

1 reference

Europe PubMed Central

15 August 2017

publication date

10 November 2012

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

16

1 reference

Europe PubMed Central

15 August 2017

2

1 reference

Europe PubMed Central

15 August 2017

373-386

1 reference

Europe PubMed Central

15 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

10 November 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

https://scigraph.springernature.com/pub.10.1007/s10456-012-9321-x

0 references

Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Specific β-tubulin isotypes can functionally enhance or diminish epothilone B sensitivity in non-small cell lung cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Chemotherapy dosing schedule influences drug resistance development in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Metronomic scheduling of anticancer treatment: the next generation of multitarget therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Multiple drug resistance mechanisms in cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Metronomic chemotherapy: new rationale for new directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Microtubules and resistance to tubulin-binding agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Tubulin-targeted drug action: functional significance of class ii and class IVb beta-tubulin in vinca alkaloid sensitivity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Tubulin proteomics: towards breaking the code.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Microtubule-targeting agents in angiogenesis: where do we stand?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Redefining the target: chemotherapeutics as antiangiogenics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

30 September 2017

Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

28 June 2018

Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

28 June 2018

Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

28 June 2018

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

28 June 2018

Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

28 June 2018

HMEC-1: establishment of an immortalized human microvascular endothelial cell line

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3595478

28 June 2018

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10456-012-9321-X

21 January 2018

Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10456-012-9321-X

21 January 2018

Tumor-associated endothelial cells with cytogenetic abnormalities.

1 reference

https://api.crossref.org/works/10.1007%2FS10456-012-9321-X

21 January 2018

Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion.

1 reference

https://api.crossref.org/works/10.1007%2FS10456-012-9321-X

21 January 2018

Glioma-associated endothelial cells are chemoresistant to temozolomide

1 reference

https://api.crossref.org/works/10.1007%2FS10456-012-9321-X

21 January 2018

ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties

1 reference

https://api.crossref.org/works/10.1007%2FS10456-012-9321-X

21 January 2018

Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells.

1 reference

https://api.crossref.org/works/10.1007%2FS10456-012-9321-X

21 January 2018

Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS10456-012-9321-X

21 January 2018

Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/23143659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/23143659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of class III β-tubulin as a marker of angiogenic perivascular cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23143659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor endothelial cells acquire drug resistance by MDR1 up-regulation via VEGF signaling in tumor microenvironment

1 reference

https://pubmed.ncbi.nlm.nih.gov/23143659

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10456-012-9321-X

1 reference

Europe PubMed Central

15 August 2017

release_x4z6ma4npfdt7k7m3bti223exe

1 reference

https://api.fatcat.wiki/v0/release/x4z6ma4npfdt7k7m3bti223exe

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36678312&oldid=1866226345"